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The calcium-sensing receptor (CaSR) regulates serum calcium concentrations. CASR loss- or gain-of-function mutations cause familial
hypocalciuric hypercalcemia type 1 (FHH1) or autosomal-dominant hypocalcemia type 1 (ADH1), respectively, but the population prev-
alence of FHH1 or ADH1 is unknown. Rare CASR variants were identified in whole-exome sequences from 51,289 de-identified individ-
uals in the DiscovEHR cohort derived from a single US healthcare system. We integrated bioinformatics pathogenicity triage, mean
serum Ca concentrations, and mode of inheritance to identify potential FHH1 or ADH1 variants, and we used a Sequence Kernel Asso-
ciation Test (SKAT) to identify rare variant-associated diseases. We identified predicted heterozygous loss-of-function CASR variants (6
different nonsense/frameshift variants and 12 different missense variants) in 38 unrelated individuals, 21 of whomwere hypercalcemic.
Missense CASR variants were identified in two unrelated hypocalcemic individuals. Functional studies showed that all hypercalcemia-
associated missense variants impaired heterologous expression, plasma membrane targeting, and/or signaling, whereas hypocalcemia-
associated missense variants increased expression, plasma membrane targeting, and/or signaling. Thus, 38 individuals with a genetic
diagnosis of FHH1 and two individuals with a genetic diagnosis of ADH1 were identified in the 51,289 cohort, giving a prevalence in
this population of 74.1 per 100,000 for FHH1 and 3.9 per 100,000 for ADH1. SKAT combining all nonsense, frameshift, and missense
loss-of-function variants revealed associations with cardiovascular, neurological, and other diseases. In conclusion, FHH1 is a common
cause of hypercalcemia, with prevalence similar to that of primary hyperparathyroidism, and is associated with altered disease risks,
whereas ADH1 is a major cause of non-surgical hypoparathyroidism.Introduction
The calcium-sensing receptor (CaSR), encoded by CASR on
chromosome 3q21.1, is a 1,078 amino acid class C G pro-
tein-coupled receptor that is highly expressed in calci-
tropic tissues including parathyroid glands and kidneys.1
CaSR has an extracellular amino-terminal domain which
binds Ca2þ (ECD, residues 1–612), a heptahelical trans-
membrane domain (TMD, residues 613–862), and a cyto-
plasmic carboxyl terminal domain (CT, residues 863–
1078).2 CaSR couples to heterotrimeric G proteins (Ga11)
and the adaptor related protein complex-2 s-subunit
(AP2s) to mediate signaling via intracellular Ca2þ (Ca2þi)
mobilization and mitogen-activated protein kinases.3,4
The importance of CaSR-mediated signaling for Ca2þ ho-
meostasis is confirmed by germline loss-of-function muta-
tions in CASR (MIM: 145980; 239200), GNA11 (MIM:
145981), and AP2S1 (MIM: 600740) that cause familial hy-
pocalciuric hypercalcemia types 1–3 (FHH1-3), respec-
tively. FHH1 accounts for 65% of cases, and is an auto-
somal-dominant condition characterized by lifelong
elevations of serum calcium concentrations and normal1Molecular and Functional Genomics, Weis Center for Research, Geisinger, Da
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tions.5 FHH1 is usually asymptomatic and requires
no intervention,5 although it has a serum biochemical
profile similar to primary hyperparathyroidism (PHPT),
which is typically treated by parathyroidectomy. Distin-
guishing FHH1 from PHPT, generally done by assessing
urinary Ca2þ excretion, i.e., 80% of FHH-affected indi-
viduals are hypocalciuric (Ca creatinine clearance ratio
[CCCR] < 0.01) versus <20% of PHPT individuals with
CCCR < 0.01,6,7 is required to prevent FHH1-affected indi-
viduals from undergoing unnecessary parathyroid surgery.
In contrast, germline gain-of-function mutations of
CASR (MIM: 601198) and GNA11 (MIM: 615361) cause
autosomal-dominant hypocalcemia types 1–2 (ADH1-2),
respectively.8 ADH1 accounts for 70% of ADH cases9
and has a biochemical phenotype opposite of FHH1, i.e.,
individuals have low serum Ca concentrations, normal or
low PTH concentrations, relative or absolute hypercalciu-
ria, and may have symptomatic hypocalcemia and ectopic
calcifications affecting the kidneys and/or basal ganglia.8
FHH1 and ADH1 are considered rare disorders, and may
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asymptomatic individuals, or in the case of ADH1,
following the presentation of an individual with symp-
tomatic hypocalcemia.10–12 However, the prevalence of
FHH1 or ADH1 remains to be determined in the general
population.10–14
The major goal of this study was to use whole-exome
sequencing and clinical laboratory data from a single large
US health system to identify individuals with FHH1 and
ADH1 and to estimate the population frequencies of these
rare disorders. To achieve this, we combined rare variant
pathogenicity triage with serum Ca measures from the
electronic health record (EHR) and verified clinically iden-
tified potential FHH1 or ADH1 individuals by heterologous
expression and functional analyses of predicted patho-
genic variants. Clinical validation of FHH1- and ADH1-
associated variants was further bolstered by in silico pedi-
gree analysis of individuals harboring rare CASR variants.
The broad expression of CaSR in cells and tissues that do
not directly contribute to serum Ca2þ homeostasis argues
that FHH1-affected individuals may have altered risks of
non-calcitropic diseases. However, systematic assessment
of these potential risks in FHH1 variant carriers has not
been possible to date due to the small numbers of individ-
uals identified in most FHH1 pedigrees. We therefore capi-
talized on the numbers of FHH1-affected individuals iden-
tified in this cohort to apply an unbiased, rare variant
binning approach to examine the non-calcitropic disor-
ders associated with elevated serum Ca concentrations
and/or reduced CaSR function.Subjects and Methods
Supplemental Methods contains additional methodological
details.
DiscovEHR Cohort
The initial Geisinger cohort consisted of 51,289 individuals,
including 563 individuals below the age of 18, who consented
to participate in the MyCode Community Health Initiative,15
and whose germline DNA underwent whole-exome sequencing
(WES) by Regeneron Genetics Center (Table S1).16 The DiscovEHR
cohort was predominantly of northern European descent (50,387
individuals), plus 57 American Indian/Alaska Native; 137 Asian;
570 Black/African American; 40 Native Hawaiian/Pacific Islander;
and 3 Uncategorized/Other, as self-reported in the EHR.
Clinical Data
All recorded clinical and biochemical measurements and unique
International Classification of Disease-9 (ICD9) codes for each in-
dividual were extracted from the EHR in a de-identified manner
through an approved data broker in accordance with Institutional
Review Board approvals. Medians and means of all available
outpatient serum and urinary biochemical and clinical parameters
were analyzed. For individuals with available albumin concentra-
tions, serum calcium (denoted as serum Ca) was adjusted for
serum albumin concentration as follows: adjusted Ca (Caalb) ¼ to-
tal serum Ca (mg/dL) þ 0.8*(4-serum albumin (mg/dL)). At least
one serum Ca measure was available in the EHR for 50,208 ofThe Ame51,289 individuals in the cohort (98%). When available in the
EHR, we report intact PTH levels, measured as part of routine
care by electrochemiluminescence at Geisinger Medical Labora-
tories, with a reference interval of 15-65 pg/mL. To determine
the contribution of carriers of rare CASR hypercalcemia-associated
variants to the fraction of patients having overt hypercalcemia,
i.e., mean serum Ca R 10.2 mg/dL, we identified the subset of in-
dividuals in the cohort not treated with either cinacalcet or
vitamin D and with at least 5 measures of serum Ca in their EHR
as an indicator of persistent hypercalcemia. Likewise, we deter-
mined the number of individuals having persistent hypocalcemia
that were not treated with either cinacalcet or vitamin D and had
at least 5 serum Ca measures and mean serum Ca of% 8.5 mg/dL.
Exome Sequencing
Exome sequencing, alignment, quality control, and variant calling
were performed as previously described.16 Sanger DNA sequencing
was used to confirm all nonsense, frameshift, and missense rare
variants with likely clinical impact.
Segregation Analysis
To leverage the power of familial transmission as a means to deter-
mine clinical significance of rare genetic variants, we compared
clinical laboratory data for related and unrelated individuals
who were carriers of the same rare FHH1- or ADH1-associated
variant. To increase the probability of identifying close relations,
we used a larger DiscovEHR cohort of 92,816 individuals.17 Relat-
edness was determined by genome-wide estimation of shared
identity by descent (IBD) using PRIMUS (Pi-HAT scores provided
in relevant tables). We identified close relations (parent-child;
full sibling; 2 relations) and their serum Ca phenotypes whether
or not they were carriers of the variant.
Association Studies
We performed a binned genetic association analysis of CASR vari-
ants to identify associated clinical traits. A large-scale simulation
study of DiscovEHR data demonstrated that Sequence Kernel Asso-
ciation Test (SKATanalysis) for case numbersR 200, assuming un-
balanced case-control ratios (as expected for different ICD9 codes),
resulted in >90% power to detect associations and had well-
controlled type I error.18 We combined all individuals with rare
variants (nonsense plus frameshift plus functionally confirmed
missense loss-of-function variants) and performed SKAT analysis
using default parameters against all ICD9 codes with a minimum
of 200 individuals in the cohort, regardless of genotype, adjusted
for sex, age, age2, and first four principal components (SKAT R
package).
Variant Analysis
Variants were identified relative to the longest CASR transcript
(transcript 1, GenBank: NM_001178065.2; 1,088 amino acid resi-
dues) in genome build GRCh37.p13. Nonsense and frameshift var-
iants were assessed for nonsense-mediated decay by in silico anal-
ysis (NMDEscpredictor). We used a stepwise approach to identify
all possible impactful missense variants. Initial triage focused on
all rare genetic variants and their predicted pathogenicity as deter-
mined by the bioinformatics pipeline (RMPath, Supplemental
Methods), designated with terms consistent with American Col-
lege of Medical Genetics and Genomics (ACMG) guildelines.19
The second step in triage extracted and analyzed all outpatient
serum Ca measures (or median serum Caalb when available) forrican Journal of Human Genetics 106, 734–747, June 4, 2020 735
Figure 1. Characteristics and Bioinformatics Triage of CASR Var-
iants in the 51,289 DiscovEHR Cohort
(A) Variants were classified into coding (missense [MISS], synony-
mous [SYN], and nonsense or frameshift [NONS/FS]) and non-cod-
ing (30 or 50 untranslated region [UTR], splice site [SPL SITE], or up-
stream/downstreammodifier [MOD]) variants. Bar graph indicates
numbers of variants in each class. The percent of variants not pre-
viously listed in variant databases is indicated above each bar.
Filled or shaded portions of bars indicate the subset of variants
new to this study (white), with RefSeq rsID number (gray) or
736 The American Journal of Human Genetics 106, 734–747, June 4,each individual. The final step in variant triage examined individ-
ual patient EHR to assess potential comorbidities that might
impact serum Ca measurements (bariatric surgery, malabsorption
syndromes, osteoporosis, and/or cancer). In cases where individ-
uals presented with potential serum Ca modifying comorbidities,
we plotted the timeline of serum Ca values to determine whether
there were non-random trends. Variants present in one ormore in-
dividuals were examined for familial associations.
Prevalence/Penetrance Estimates for FHH1 and ADH1
Prevalence of FHH1 or ADH1 in unrelated individuals of the
cohort was determined after removal of one individual of each
related pair of carriers of LoF (denoting frameshift or nonsense var-
iants) and mLoF (denoting missense loss of function) variants
(FHH1) or mGoF (denoting missense gain of function) variants
(ADH1). Familial penetrance was determined as the fraction of
related carriers with the serum Ca phenotypes (mean serum Ca
R 10.2 mg/dL for FHH1; mean serum Ca % 8.5 mg/dL for
ADH1) normalized to total related carriers.
Functional Characterization of Rare Variants
Expression and Plasma Membrane Targeting
Point mutations, generated by polymerase chain reaction in the
most prevalent human CaSR transcript (GenBank: NM_000388.
4, 1,078 amino acid residues; missing amino acid residues 537–
547 of the longest predicted CaSR transcript [GenBank:
NM_001178065.2]) in a FLAG-tagged CaSR cDNA (FLAG-CaSR in
pcDNA3.1), were confirmed by sequencing (Genewiz) and tran-
siently transfected into HEK293 cells (FuGENE HD, Promega).
Plasma membrane targeting was determined by enzyme-linked
immuno-absorbance assays (ELISA) with HRP-conjugated anti-
FLAG antibody (Sigma-Aldrich) as previously described.20 ELISA
detects the N-terminally expressed FLAG tag on the CaSR con-
structs and does not detect a specific CaSR epitope. Protein expres-
sion and processing to the mature form was assessed on western
blots of lysates probed with a custom rabbit anti-CaSR antibody
generated against the LRG extracellular epitope (amino acid
residues 374–391),20 a region that did not encompass any of the
studied variants.
Intracellular Calcium (Ca2þi) Measurements
We chose to functionally characterize CaSR variants by measuring
extracellular Ca2þ (Ca2þe)-evoked changes in Ca
2þ
i, since this is
the pathway to which CaSR preferentially couples and is most
commonly used for human variant analysis.2 Ca2þi responses
induced by graded increases in Ca2þe in cells loaded with thewithout ID but found in population variant databases
(crosshatched).
(B) Histogram of the common plus rare variant distribution in the
51,289 individual DiscovEHR cohort: 30,676 individuals had a sin-
gle variant and 20,514 individuals had two or more variants (com-
mon þ rare).
(C) Raremissense variants (n¼ 108) were sorted into those with (n
¼ 4) and without (n ¼ 104) ClinVar annotation. Variants were tri-
aged by RMPath (see Supplemental Subjects and Methods) from
variants of unknown significance into those predicted to be
benign (pB), likely benign (pLB), likely pathogenic (pLP), and
pathogenic (pP). Analysis of serum Ca concentrations allowed
further sorting of all heterozygous missense variants into likely
benign (LB), missense loss-of-function (mLoF), and missense
gain-of-function (mGoF) categories. MAF, minor allele frequency;
SYN, synonymous variant; N/FS, nonsense or frameshift variant;
MISS, missense variant; VUS, variant of unknown significance.
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Figure 2. Serum Ca Concentrations for
Individuals Having LoF or Rare Missense
Variants in the DiscovEHR Cohort
(A) Box and whisker plot in the style of Tu-
key (points indicating outliers) of all serum
Ca measures from the EHR summed for all
individuals having the same nonsense or
frameshift variant (# of individuals). White
boxes indicate variants predicted to un-
dergo NMD, gray boxes indicate variants
predicted to escape NMD, and dotted lines
mark the normal serum Ca concentration
range from 8.5 to 10.2 mg/dL. Also plotted
is the mean 5 SD of all individuals
(15,922) having no rare variants but
homozygous for the reference (REF) haplo-
type (Ala986/Arg990/Glu1011, residue
numbering corresponding to GenBank:
NM_000388.4). ****p < 0.0001.
(B) Upper plot presents the time series of
serum Ca measures for an individual with
a heterozygous Trp293* variant, showing
a significant decrease in mean total serum
Ca concentrations in December 2011,
when treatment with cinacalcet began,
as indicated by vertical dotted line (p <
0.0001). Means and 95% confidence in-
tervals are plotted (mean prior to cinacal-
cet initiation, 11.23 5 0.69 mg/dL, 95%
C.I., 10.95–11.5 mg/dL; after cinacalcet
initiation, 10.15 5 0.69 mg/dL, 95%
C.I., 9.81–10.48 mg/dL). Cinacalcet was
continued through the beginning of
2015 and had a statistically significant effect on serum Ca concentrations (p < 0.0001). Lower plot indicates serum PTH values
determined before and after cinacalcet initiation; differences in mean values were not significant.
(C) SerumCameans (box andwhiskers in style of Tukey with points indicating outliers) were plotted for individuals homozygous for the
REF haplotype (15,922 individuals), and carriers of ClinVar and rare missenseCASR variants that affect serumCa concentrations (residue
numbering according to GenBank: NM_000388.4). The number of carriers of each variant having serum Ca measures in the EHR are
noted in parentheses. Dotted lines mark the normal range for serum calcium (8.5–10.2 mg/dL). Statistically significant differences be-
tween groups was determined by ANOVA (**p < 0.01, ****p < 0.0001).Ca2þ indicator dye Fluo-4 were measured with a PHERAstar instru-
ment (BMG Labtech) at 37C, as previously described (Supple-
mental Methods).21 Assays were performed in four biological rep-
licates in HEK293 cells transiently transfected with WT (¼
reference sequence) or CaSR variant cDNAs. The F-test was used
for statistical analyses.9,21Results
Identification and Triage of Rare CASR Variants
CASR variants in the 51,289 individual DiscovEHR cohort
were identified and classified as coding (missense, synony-
mous, nonsense, or frameshift) or non-coding (30 or 50
UTR, splice site, or downstream/intronic or modifier) vari-
ants (Figure 1A). Sixty percent (30,676 of 51,289 individ-
uals) had at least one common or rare CASR variant which
might impact serum calcium (309 total variants,
Figure 1B). A total of 205 different rare (mean allele fre-
quency [MAF] < 0.01) coding variants were identified in
883 individuals, including 92 variants that were not found
in public databases (dbSNP, ExAC [now in gnomAD], 1000
Genomes, or ESP). There were no significant domain biases
in variant localization (Figure S1). Rare synonymous (91)
and potential splice site variants (3) were not further pur-The Amesued. We identified 6 nonsense/frameshift variants in 20
individuals. To assess the clinical impact of the rare
missense variants, a two-tier triage based on bioinformatics
assessment and measured serum Ca concentrations was
undertaken (Figure 1C). Of the 57 variants predicted to
be likely pathogenic (pLP) or pathogenic (pP), 12 were
associated with hypercalcemia in 23 individuals, and 2
hypocalcemia-associated variants were identified in 3
individuals (Figure S2). Thus bioinformatics reduced the
query set to 55% of total rare variants (57 LP/P variants
from a total of 104), and subsequent serum Ca concentra-
tion analysis identified the 25% of total rare variants that
were potentially associated with FHH1 or ADH1 pheno-
types. None of the variants predicted to be likely benign
(pLB) or benign (pB) had individuals with serum Ca con-
centrations at the outer limits of the normal range, and
they were not further investigated.
Serum Ca Concentrations of Carriers of CASR Nonsense,
Frameshift, or Missense Variants
Six nonsense or frameshift variants were identified (¼ N/FS,
Figure 1C; [transcript 1, GenBank: NM_001178065.2]). The
four variants that were localized in the ECD (c.108dup
[p.Leu37Alafs*11], c.303C>A [p.Cys101*], c.679C>Trican Journal of Human Genetics 106, 734–747, June 4, 2020 737
Table 1. Demographics, Laboratory Values, and Variant Burden of Heterozygous Carriers of CASR Nonsense and Frameshift Variants
Sex Age (year)









F 49 10.6 5 0.4 (16) [9.9–10.7] 10.5 0.14 5 0.029 (3) 46.5 5 14.3 (8) [24–71]
M 74 10.7 5 0.4 (23) [9.9–11.4] 10.7 N/A 127.5 5 48 (6) [74–208]
M 72 10.8 5 0.3 (7) [8.8–11.2] 10.7 N/A 33(1)
F 61 10.5 5 0.4 (12) [10.3–11.0] 10.4 0.023 (1) 129.8 5 0.43 (8) [66–209]
M 44 10.3 5 0.2 (3) [10.0–10.4] 10.4 N/A N/A
c.303C>A (p.Cys101*)
F 33 10.2 5 0.4 (7) [9.3–10.4] N/A N/A N/A
M 83 10.5 5 0.7 (164) [9.7–11.7] 10.5 0.171 (1) 53.7 5 30 (14) [26–124]
c.679C>T (p.Arg227*)
F 65 10.5 5 0.4 (28) [9.9–11.3] 10.2 0.057 (1) 73.6 5 16 (5) [56–90]
F 73 10.6 5 0.2 (3) [10.5–10.8] 9.5 0.049 (1) 45.6 5 8 (3) [38–54]
M 45 10.0 5 0.4 (5) [9.4–10.2] N/A N/A 45 (1)
M 68 10.0 5 0.4 (24) [9.5–10.5] 9.72 N/A 146.5 5 13.4 (2) [137–156]
F 32 9.9 (1) N/A N/A N/A
c.879G>A (p.Trp293*)
F 77 10.5 5 1.0 (54) [8.5–12.0] 10.01 0.133 5 0.04 (2) 64.7 5 21 (12) [40–102]
c.2674A>T (p.Lys892*)
F 26 10.7 5 0.4 (16) [10.1–11.6] 10.37 N/A 51.3 5 11 (9) [39–75]
c.3074delC (p.Pro1025Argfs*9)
M 90 8.4 5 0.4 (4) [8.4–9.4] N/A N/A N/A
F 64 9.7 5 0.3 (9) [9.2–10.2] N/A N/A N/A
F 74 10.1 5 0.3 (7) [9.5–10.7] 10.1 N/A 42.8 5 9.8 (5) [33–54]
F 81 10.3 5 0.5 (7) [9.7–11.2] N/A N/A 41 (1)
F 81 9.5 5 0.4 (16) [8.9–10.2] N/A N/A 56 (1)
M 25 9.4 (1) N/A N/A N/A
We present both mean serum Ca, and when available, albumin-corrected median serum Ca values, urinary Ca, and serum PTH values. N/A, no measures available
in the EHR. Only the individual with the p.Trp293* variant was treated with cinacalcet; no individuals were treated with vitamin D during the time period of serum
Ca measures. Genomic variants are designated relative to the CASR reference sequence (GenBank: NM_001178065.2).
aNormal range for serum Ca is 8.5–10.2 mg/dL.
bNormal range for urinary Ca is 0.1–0.25 g/24 h.
cReference range for intact serum PTH is 15–65 pg/mL.[p.Arg227*], c.879G>A [p.Trp293*]) were predicted to un-
dergo nonsense-mediated mRNA decay (NMD), while two
variants in the CaSR CT (c.2674A>T [p.Lys892*],
c.3074delC [p.Pro1025Argfs*9]) escape NMD and are pre-
dicted to result in truncated receptors. The variants subject
to NMDwere identified in 13 individuals and had an aggre-
gate mean serum Ca concentration significantly higher
than the 7 individuals with non-NMD variants (NMD,
10.57 5 0.63 [n ¼ 268 values] versus non-NMD, 10.03 5
0.56 [n ¼ 86 measures], p < 0.0001 by two-tailed t test). In-
dividuals with either class of nonsense/frameshift variant
had mean serum Ca concentrations significantly higher
than individuals having no rare variants and homozygous
for the reference (REF) haplotype (corresponding to738 The American Journal of Human Genetics 106, 734–747, June 4,Ala986/Arg990/Glu101; residue numbering based on Gen-
Bank: NM_000388.4) (Ca 9.39 5 0.34, n ¼ 15,922, p <
0.0001 by one-way ANOVA) (Figure 2A and Table 1). Avail-
able EHR data confirm that most hypercalcemic individuals
heterozygous for nonsense/frameshift variants had normal
or slightly elevated serum PTH levels, and urinary Ca levels
below the normal range, consistent with the FHH1 pheno-
type (Table 1). The individual heterozygous for c.879G>A
(p.Trp293*) had longitudinal EHR data that documented
the effect of the allosteric activator of CaSR, cinacalcet (Sen-
sipar), on serum Ca concentrations. Serum Ca was consis-
tently elevated (10.2–12 mg/dL) prior to treatment (all mea-
sures plotted in Figure 2B), then decreased into the high-
normal range after initiation of treatment. Cinacalcet2020
Table 2. Demographics, Laboratory Values, and Variant Burden of Heterozygous Carriers of Rare CASR Missense Variants
Sex Age (year)









M 64 8.25 5 0.4 (18) [7.5–8.8] 8.16 N/A N/A
c.965T>C (p.Leu322Pro)
F 55 7.8 5 0.6 (12) [6.9–8.5] 7.49 N/A 28.8
M 79 8.6 5 0.9 (54) [7.5–9.1] 7.5 N/A 14.7 5 6.6 (7) [7–26]
c.55G>C (p.Ala19Pro)
M 69 10.23 5 0.4 (10) [9.5–10.6] N/A N/A N/A
F 35 10.3 (1) N/A N/A N/A
c.197G>A (p.Arg66His)
M 82 10.5 5 0.5 (80) [8.5–11.4] 10.62 N/A 94 (1)
F 60 10.43 5 0.3 (5) [10.3–10.7] N/A N/A N/A
c.220A>C (p.Met74Leu)
M 63 10.6 5 0.4 (2) [10.3–10.9] N/A N/A N/A
c.1183T>C (p.Cys395Arg)
F 65 10.8 5 0.4 (16) [9.9–11.6] 10.64 0.100 (1) 49.5 5 16.5 (11) [21–77]
F 40 10.94 5 0.5 (9) [10.1–11.3] N/A 0.12 5 0.019 (2) 29 5 7.4 (9) [18–43]
M 44 10.9 5 0.4 (13) [10.3–11.5] 10.25 N/A 34 (1)
c.1197G>C (p.Glu399Asp)
F 55 10.2 5 0.4 (5) [9.8–10.6] N/A N/A N/A
c.1250C>G (p.Ser417Cys)
M 55 10.1 5 0.3 (24) [9.6–10.8] 9.8 N/A 12.5 5 3.5 (2) [10–15]
F 23 N/A N/A N/A N/A
M 65 10.4 5 0.6 (5) [9.8–11.3] N/A N/A N/A
F 70 9.87 5 0.3 (3) [9.7–10.2] N/A N/A 70.5 5 23.3 (2) [54–87]
F 42 10.1 5 0.3 (3) [9.8–10.4] N/A N/A N/A
c.1288G>A (p.Ala430Thr)
F 70 10.1 5 0.3 (16) [9.7–11.0] 9.8 N/A N/A
M 72 10.4 5 0.3 (65) [9.7–11.0] 10.28 N/A 33 (1)
c.1309T>C (p.Cys437Arg)
M 85 11.1 5 0.4 (46) [10.2–11.9] 11.18 0.131 5 0.01 (2) 33.5 5 10.8 (4) [18–41]
F 73 9.4 5 0.3 (6) [9.0–9.7] N/A N/A 127 (1)
c.1979T>C (p.Leu660Pro)
F 65 10.8 5 0.4 (27) [9.6–11.4] 10.76 0.06 5 0.03 (2) 43.7 5 7.8 (9) [33–53]
c.2068C>T (p.Arg690Cys)
F 76 9.86 5 0.4 (27) [8.8–10.5] 9.65 N/A N/A
c.2205C>G (p.Phe735Leu)
F 69 10.0 5 0.27 (17) [9.7–10.8] 9.68 N/A N/A
(Continued on next page)
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Table 2. Continued
Sex Age (year)









F 64 9.9 5 0.4 (54) [9–10.7] 9.12 N/A N/A
M 43 10.0 5 0.3 (25) [9.5–10.6] 9.58 N/A N/A
We present both mean serum Ca, and when available, albumin-corrected median serum Ca values, urinary Ca, and serum PTH values. N/A, no measures available
in the EHR. No individuals were treated with cinacalcet or vitamin D during the time period of serum Ca measures. Genomic variants are designated relative to the
CASR reference sequence (GenBank: NM_001178065.2).
aNormal range for serum Ca is 8.5–10.2 mg/dL.
bNormal range for urinary Ca is 0.1–0.25 g/24 h.
cReference range for intact serum PTH is 15–65 pg/mL.caused a reduction in serum PTH concentrations into the
normal range, although the differenceswere not statistically
significant, likely due to the low number of measures under
each condition (73.0 5 12.4 pg/mL, n ¼ 5, before treat-
ment; 63.8 5 9.7 pg/mL, n ¼ 5, on cinacalcet; p ¼ 0.23)
(Figure 2B). The two urinary Ca measures available in the
EHR were both acquired prior to initiation of cinacalcet
treatment and were uninformative as to the effect of cina-
calcet (Table 1). Overall, results confirm that CaSR
nonsense/frameshift variants promote hypercalcemia.
Four variants in the cohort were found in ClinVar (Clin-
ical Variant database), an NCBI archive of medically impor-
tant human variation, and were scored as variants of un-
known significance (VUS) (c.740C>T [p.Ser247Phe],
c.2807A>G [p.Gln936Arg], c.3151C>T [p.Arg1051Trp])
or benign/likely benign (c.3121G>A [p.Gly1041Ser]) (tran-
script 1, GenBank: NM_001178065.2). Despite the means
of all individual carriers for each ClinVar variant being in
themiddle quartiles of the normal serumCa concentration
range (8.925–9.775 mg/dL), individuals with p.Ser247Phe
and p.Arg1041Trp variants had significantly lower mean
serum Ca concentrations than individuals homozygous
for the reference CASR haplotype (p.Ser247Phe, 9.21 5
0.44 mg/dL [10 individuals], p < 0.0001 versus REF;
p.Arg1051Trp, 9.33 5 0.59 mg/dL [22 individuals], p ¼
0.005 versus REF; REF 9.39 5 0.38 mg/dL [15,922 individ-
uals]). However, neither p.Gln936Arg (9.385 0.55 mg/dL,
43 individuals) nor p.Gly1041Ser (9.2 5 0.42 mg/dL, 3 in-
dividuals) significantly altered mean serum Ca concentra-
tions relative to CASR REF. Similar analyses were done on
the 14 pLP and pP variants having serumCa concentration
distributions at the outer limits of the normal range. We
identified 13 hypercalcemic individuals (mean serum Ca
concentrations R 10.2 mg/dL) who were carriers of 9
distinct rare variants consistent withmissense loss-of-func-
tion (mLoF) variants, and 3 variants in 8 individuals were
associated with serum Ca concentrations that were signif-
icantly elevated relative to the CASR REF haplotype (p <
0.0001), i.e., in the upper quartile of normal (9.775–
10.2 mg/dL). Two missense variants were associated with
low serumCa concentrations (means% 8.5mg/dL) in 3 in-
dividuals, consistent with missense gain-of-function
(mGoF) mutations (Figure S2, clinical data in Table 2).740 The American Journal of Human Genetics 106, 734–747, June 4,In 41,489 individuals not treated with cinacalcet
or vitamin D, we identified 333 individuals (0.78%) with
overt hypercalcemia (R10.2 mg/dL, range 10.2
to 12.8 mg/dL); the 25 individuals with rare LoF or mLoF
CASR variants having mean serum Ca concentrations R
10.2 mg/dL represented 7.5% of overtly hypercalcemic in-
dividuals. There were 1,699 individuals with hypocalcemia
(mean serum Ca concentration % 8.5 mg/dL, range 6.3 to
8.5 mg/dL) who were not taking cinacalcet or vitamin D;
the 3 individuals with rare CASR mGOF variants represent
0.18% of hypocalcemic individuals.
Concordance of FHH1 and ADH1 Phenotypes in Related
Individuals
Table 3 illustrates the results for carriers of LoF (9 kin-
dreds, 4 variants) and missense (11 kindreds, 9 variants)
variants that demonstrate familial hyper- or hypocalce-
mia. Available clinical values of related individuals sup-
port the causal impact of CASR haplo-insufficiency in
elevated mean/median serum Ca concentrations (Table
3). As suggested by the aggregate data in Figure 2A, indi-
viduals with the p.Pro1025Argfs*9 variant were at the
high end of normal serum Ca concentrations and rela-
tions without the variant consistently had lower serum
Ca concentrations. A similar pattern of autosomal-domi-
nant inheritance of serum Ca concentrations was
observed for carriers of CASR missense variants (Table 3).
Overall, relatedness analysis was consistent with auto-
somal-dominant inheritance of serum Ca concentrations
in heterozygous carriers of CASR variants.
Functional Characterization of the CaSR mGoF/mLoF
Variants
The means of all serum Ca measures combined for all in-
dividuals heterozygous for each ClinVar and potential
FHH1 or ADH1 missense variants are plotted in
Figure 2C. Individuals with putative mGoF variants had
significantly reduced mean serum Ca concentrations
while all individuals having mLoF variants had mean
serum Ca concentrations significantly higher than the
REF (¼ ARE) haplotype and 9 of 12 variants had individ-
uals who were overtly hypercalcemic (R10.2 mg/dL)
(Figure 2C). To validate pathogenicity predictions for2020
Table 3. Relatedness of Heterozygous Carriers of Rare Nonsense, Frameshift, and Missense Variants in CASR, and Serum Ca, Albumin-










Ca gb (# measures)
PTH pg/mLc
(# measures) Relatednessd Pi-HAT
Nonsense/Frameshift Variants
p.Leu37Alafs*11 44 M 10.3 5 0.23 (3) 10.4 N/A N/A proband* 0.5
p.Leu37Alafs*11 61 F 10.5 5 0.35 (12) 10.4 0.23(1) 139.4 (8) parent*
p.Leu37Alafs*11 74 M 10.7 5 0.4 (23) 10.7 N/A 127.4 5 48 (6) proband* 0.5304
none 77 F 9.93 5 0.37 (28) 10.0 N/A 47.5 5 9.3 (4) full sibling
p.Cys101* 33 F 10.2 5 0.4 (7) 10.4 N/A N/A proband* 0.2537
p.Cys101* 83 M 10.9 5 0.4 (28) 10.9 0.171 (1) 47.6 5 27 (11) 2*
p.Arg227* 65 F 10.5 5 0.44 (28) 10.4 0.057 (1) 73.6 5 16 (5) proband*
none 90 F 9.83 5 0.4 (53) 9.9 N/A N/A parent 0.5
none 47 M 9.7 5 0.3 (8) 9.6 N/A N/A child 0.5
none 71 F 9.6 5 0.4 (28) 9.5 N/A N/A full sibling 0.5578
p.Arg227* 45 M 10.13 5 0.4 (8) 10.2 N/A 45 (1) proband* 0.2513
none 55 M 9.49 5 0.53 (19) 9.6 N/A 18 (1) 2
p.Arg227* 68 M 9.95 5 0.4 (24) 10 N/A 146.5 5 13 (2) proband* 0.5112
none 63 F 9.32 5 0.2 (11) 9.3 N/A 41.5 5 21.5 (2) full sibling
p.Pro1025Argfs*9 64 F 9.67 5 0.34 (9) 9.7 N/A N/A proband*
none 81 F 9.64 5 0.3 (12) 9 N/A N/A parent 0.5142
none 84 M 9.22 5 0.3 (32) 9.2 N/A N/A 2 0.2413
none 32 F 9.3 5 0.35 (3) 9.1 N/A N/A 2 0.2889
p.Pro1025Argfs*9 74 F 10.1 5 0.3 (27) 10.2 N/A 42.8 5 9.8 (4) proband*
none 27 M 9.7 (1) 9.7 N/A N/A 2 0.299
none 29 M 9.68 5 0.39 (12) 9.5 N/A N/A 2 0.2142
p.Pro1025Argfs*9 81 F 9.64 5 0.3 (25) 9.6 N/A 56 (1) proband*
none 84 M 9.22 5 0.3 (32) 0.2 N/A N/A full sibling 0.4886
none M 63 9.28 5 0.35 (5) 9.1 N/A 47.3 5 16 (4) 2 0.2455
none 32 F 9.3 5 0.4 (3) 9.1 N/A N/A 2 0.2917
Missense Variants
p.Asp23Glu 64 M 8.25 5 0.4 (18) 8.3 N/A N/A proband* 0.5787
none 69 M 9.0 5 0.3 (9) 9 N/A N/A full sibling
p.Leu322Pro 56 F 8.39 5 0.4 (154) 8.4 N/A 30.2 5 13 (10) proband*
p.Leu322Pro 79 M 8.6 5 0.9 (54) 8.3 N/A 14 5 6.1 (9) parent* 0.4946
none 77 F 9.95 5 0.5 (29) 10 N/A 33 (1) parent 0.4977
p.Ala19Pro 69 M 10.23 5 0.41 (10) 10.2 N/A N/A proband* 0.5093
p.Ala19Pro 40 F 10.2 5 0.3 (8) 10.1 N/A N/A child*
pAla19Pro 35 F 10.3 10.3 N/A N/A proband* 0.1918
none 79 M 9.01 5 0.34 (10) 9 N/A N/A 2
p.Arg66His 60 F 10.44 5 0.3 (4) 10.5 N/A N/A proband* 0.2425
p.Arg66His 70 M 10 5 0.3 (61) 10 N/A N/A 2*
p.Cys395Arg 65 F 10.84 5 0.4 (16) 10.9 0.1 (1) 49.5 5 17 (11) proband* 0.5
(Continued on next page)











Ca gb (# measures)
PTH pg/mLc
(# measures) Relatednessd Pi-HAT
p.Cys395Arg 40 F 10.94 5 0.5 (9) 10.9 0.13 5 0.02 (2) 29 5 7.4 (9) child*
none 60 M 9.4 5 0.24 (4) 9.2 N/A N/A 2 0.1898
p.Glu399Asp 55 F 10.2 5 0.4 (5) 10.4 N/A N/A proband* 0.1893
none M 65 9.2 5 0.24 (6) 9.2 N/A N/A 2
p.Ser417Cys 65 M 10.4 5 0.6(5) 10.3 N/A N/A proband* 0.5037
none 66 F 9.29 5 0.33 (9) 9.3 N/A N/A full sibling
p.Ser417Cys 55 M 10.13 5 0.33 (24) 10.1 N/A 12.5 5 3.4 (2) proband*
p.Ser417Cys 90 F 10.1 5 0.3 (18) 10.1 N/A 40 (1) 2* 0.298
none 74 M 9.18 5 0.23 (11) 9.2 N/A N/A full sibling 0.5272
p.Leu660Pro 45 F 10.5 (1) 10.5 N/A N/A proband* 0.2201
p.Leu660Pro 65 F 10.9 5 0.4 (27) 10.9 0.06 5 0.03 (2) 43.7 5 7.8 (9) 2*
p.Arg690Cys 76 F 9.87 5 0.4 (27) 10 N/A N/A proband* 0.3389
none 55 M 9.14 5 0.44 (4) 9.1 N/A N/A 2
N/A, no measures in EHR. Parent-Child (P-C), full sibling, or 2 (unspecified) relations are listed. Genomic variants are designated relative to the CASR reference
sequence (GenBank: NM_001178065.2).
aNormal range for serum Ca is 8.5–10.2 mg/dL.
bNormal range for urinary Ca is 0.1–0.25 g/24 h.
cReference range for serum PTH is 10–65 pg/mL.
dAsterisk indicates variant carrier.the putative mGoF and mLoF variants, we introduced
each into a human FLAG-tagged CaSR (based on tran-
script GenBank: NM_000388.4) construct by site-
directed mutagenesis, and transiently transfected wild-
type (WT ¼ REF) or mutant constructs into HEK293 cells,
as described.20
We compared protein levels and plasma membrane
targeting of each mGoF and mLoF variant relative to
WT by western blotting and ELISA.20 The antibodies
used for these studies targeted either an inserted epitope
(amino terminal FLAG, used for ELISA) or an endogenous
ECD sequence (LRG epitope, residues 374–391, used for
western blotting) that did not contain tested variants.
The mGoF variants increased total and plasma mem-
brane protein levels whereas mLoF variants reduced
total and plasma membrane protein levels relative to
WT CaSR, Figures 3A and 3B (representative western
blot in Figure S3). To assess WT and variant function,
we measured Ca2þi mobilization in response to
alterations in Ca2þe concentrations in transiently trans-
fected cells.22 Fitting of the Ca2þe concentration-
response curves (Figures S4-S5) showed that mGoF vari-
ants had significantly reduced EC50s, i.e., [Ca
2þ
e] at
half-maximal response, whereas the 12 mLoF variants
had significantly increased EC50s relative to WT CaSR
(Figure 3C). These combined studies demonstrate altered
protein expression, plasma membrane localization, and/
or activation by Ca2þe consistent with predicted mGoF
or mLoF variants, as revealed by effects on serum calcium
concentrations.742 The American Journal of Human Genetics 106, 734–747, June 4,Prevalence Estimates for FHH1 and ADH1 in the
DiscovEHR Cohort
The clinical and functional data identify genetic variants
that are associated with FHH1 or ADH1. We estimated
the prevalence of these variants in the cohort and
compared them with other know causes of hyper- or hy-
pocalcemia (Figures 4A and 4B). Thirty-eight unrelated
individuals (one of each related pair were removed
from the analysis), yielded a prevalence of 74.1 per
100,000. Two unrelated individuals with ADH1 yielded
a prevalence of 3.9 per 100,000. To estimate familial
penetrance, i.e., the proportion of hypercalcemic rela-
tives, we identified the subset of related individuals
with genetic variants that expressed the serum Ca
phenotype, i.e., for FHH1 the estimated familial pene-
trance was 92% (23 of 25 related individuals had mean
serum Ca R 10.2 mg/dL) and for ADH1, estimated famil-
ial penetrance was 100% (Tables 1 and 2).
Association of FHH1 CASR Variants with Major Disease
Phenotypes
We assessed whether genetically determined lifetime mildly
elevated serum Ca concentrations and/or reduced func-
tional activity of CaSR altered the risks of common non-cal-
citropic diseases. All individuals having CASR loss-of-func-
tion variants (nonsense plus mLoF missense variants),
were combined for burden testing using the Sequence
Kernel Association Test (SKAT). All significant associations
are listed in Table 4. Top diseases associated with elevated
serum Ca concentrations and/or reduced CaSR function2020
Figure 3. Biochemical and Cellular Analysis of mLoF and mGoF
CaSR Mutations
(A) Plot presents mean 5 SD of western blot analysis of lysates
from three independent HEK293 cell transfections, as the percent
of mature receptors ([mature/(immature þ mature)]%) for
WT (black bar), mGoF (white bars), and mLoF (gray bars) variants.
Representative western blots presented in Figure S3. Statistical
analysis was by Student’s t test, with *p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001.
(B) Plasma membrane localization was determined for WT (black
bar), mGoF (white bars), and mLoF (gray bars) variants by ELISA
of transiently transfected HEK293 cells, plotted as the mean 5
SD of the percent of surface to total expression, for at least three
independent experiments. Statistical analysis was by Student’s t
test, with *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
(C) Bar graph of EC50 values forWT (black bar), mGoF (white bars),
and mLoF (gray bars) variants extracted from fits of dose-response
relations for Ca2þe. Statistical analysis by F-test, with ****p <
0.0001. Titrations were done as described in Subjects and
Methods, and plots of dose-response relations which were fitted
to extract EC50s are presented in Figures S5 and S6. Numbering
of residues for all graphs based on GenBank: NM_000388.4.include cardiovascular disease, including embolism and
thrombosis, chronic diastolic heart failure, and paroxysmal
ventricular tachycardia (Figure 4C, Table 4), and neurolog-
ical disorders, including major depression, dementia, and
alcohol abuse. In addition, CASR loss-of-function variants
were associated with neck of femur fractures (Table 4),
although the variants were not significantly associated
with osteoporosis. The small number of individuals with
mGoF variants precluded disease association analysis.Discussion
The availability of whole-exome sequence data from
51,289 individuals from a single health system coupledThe Amewith phenotype-rich EHR data has provided a unique op-
portunity to determine the prevalence of FHH1- and
ADH1-associated CASR variants. CASR missense loss- or
gain-of-function variants are particularly difficult to iden-
tify with pathogenicity prediction tools alone.24 Our strat-
egy was designed to overcome the main drawbacks of
working with de-identified data that was not specifically
obtained to diagnose FHH1 or ADH1 in small pedigrees,
i.e., incomplete clinical data for definitive diagnosis. We
combined WES, available clinical data, and statistical esti-
mates of the relatedness of de-identified CASR variant car-
riers to other individuals in a larger sequenced population.
The combined results support the expected autosomal-
dominant inheritance of the FHH1 and ADH1 clinical phe-
notypes for the identified variants. Results were further
validated by in vitro functional analyses. In 51,289 individ-
uals, we identified 14 different rare missense variants
which could be linked to FHH1 or ADH1. Our approach
accurately identified previously known FHH1 variants in
the cohort, including p.Cys395Arg25 and p.Arg680Cys.26
FHH1 is generally considered a rare disorder, i.e., a study
of known FHH kindreds from the West of Scotland re-
ported a minimum prevalence of 1.3 cases in 100,000,13
in the range of other monogenic hypercalcemic disorders
including multiple endocrine neoplasia type 1 (MEN1)
syndrome (3.3–10 cases per 100,000 [Orphanet database]).
The DiscovEHR cohort genetic prevalence for FHH1, which
includes normocalcemic individuals, is 74 cases per
100,000, of which 49/100,000 had the FHH1 phenotype
(38-fold higher than previous estimates), in the range
of the age-adjusted prevalence of classical PHPT of 48 per
100,000 in adult males14 and 120 per 100,000 for adult
females14 (Figure 4A). In a recent study of individuals being
evaluated for hypercalcemia, 6.1% of patients had rare
CASR variants, 47% of which were not previously re-
ported.27 Moreover, this study independently confirmed
three of the FHH1-associated variants identified in the cur-
rent study, p.Arg227*, p.Ala430Thr, and p.Arg680Cys.27
The substantially higher prevalence of FHH1 when esti-
mated at the population level highlights the importance
of testing for FHH in all individuals with suspected
PHPT, to avoid unnecessary parathyroidectomy.6,28,29
Finally, our study provides a prevalence estimate for
ADH1 of 3.9 cases per 100,000, in the range of the esti-
mated prevalence of 5.8 cases per 100,000 for non-surgical
hypoparathyroidism in the adult U.S. population23
(Figure 4B). Thus, ADH1 likely represents a major cause
of non-surgical hypoparathyroidism.
Our analysis suggests heterozygous nonsense/frameshift
variants may be a more common cause of FHH1 than previ-
ously reported,2 i.e., 12 of 25 FHH1 individuals had
nonsense/frameshift variants. Further, the presence of suffi-
cient individuals with nonsense/frameshift variants that are
subject to or escape from NMD-mediated mRNA decay pro-
vides preliminary evidence to suggest the conclusion that
NMD-mediated haplo-insufficiencymay produce amore se-
vere Ca phenotype than generation of prematurelyrican Journal of Human Genetics 106, 734–747, June 4, 2020 743
Figure 4. Prevalence of FHH1 and ADH1
in DiscovEHR Cohort
(A) FHH1 prevalence in the DiscovEHR
cohort (black bar) compared to the age-
adjusted prevalence ofmale PHPT (mPHPT,
white bar) and female PHPT (fPHPT, gray
bar) cases reported in a large US cohort.14
(B) ADH1 prevalence in the DiscovEHR
cohort (black bar) compared with preva-
lence of non-surgical hypoparathyroidism
(non-surg HypoPT, white bar) and all forms
of hypoparathyroidism (Total HypoPT,
gray bar), estimated for the entire insured
adult US population.23
(C) Manhattan plot of SKAT analysis used
to detect disease associations defined by
ICD9 codes for a binned group of all LoF
plus mLoF variants. Labels indicate top as-
sociations with phenome-wide signifi-
cance, which include all results above the
dotted line, p< 0.05, corrected for multiple
testing. Variants included in analysis and
all significant results are in Table 4.truncated receptors. FHH1 familial penetrance, i.e., propor-
tion of hypercalcemic relatives, in this cohort (92%) was
comparable to the >95% penetrance reported in FHH fam-
ily studies,30 despite the limited size of most pedigrees and
the potential range of comorbidities that may lower serum
Ca concentrations, including renal impairment and/or
vitamin D deficiency. For those singletons without related
individuals in the cohort, a time-dependent mapping of in-
dividual clinical measures correlated with both contempo-
raneous ICD9 coding and the full range of prescription
and non-prescription medications would provide a more
comprehensive means of defining the impact of the variant
on serum Ca concentrations. Nevertheless, our integrated
approach has identified rare CASR variants causing FHH1
and ADH1 using the most readily available clinical data
and without imposition of significant assumptions and
can be readily generalizable to other clinical populations.
FHH1 is considered a benign disorder, limited to lifetime
mildly elevated serum Ca concentrations. We took advan-
tage of the sufficient numbers of individuals having
nonsense/frameshift ormissense LoF variants in the current
cohort todeterminewhether lifetimeelevated serumCacon-
centrations and/or reducedCaSR activity are associatedwith
altered risksof common(R1:250)non-calcitropicdiseases in
the U.S. population.18,31 Strong associations were found
with cardiovascular diseases, including embolism and
thrombosis and diastolic heart failure, and with major
depression (Figure 4C, Table 4). The associations identified744 The American Journal of Human Genetics 106, 734–747, June 4, 2020by SKAT analysis do not provide direc-
tionality, but the risks of embolism/
thrombosis and diastolic heart failure
have been shown to be influenced by
serumCa concentrations;32,33 likewise,
neuropsychiatric disorders have been
associated with serum Ca concentra-
tions in small case-control studies.34,35CaSR is widely expressed in the cardiovascular36,37 and ner-
vous38 systems, and it remains to be determined whether
these disease associations result fromelevated serumCa con-
centrations, reduced CaSR function, or both.
Overall, the benefits of our study are the ability to
consider a broad range of clinical conditions in an unbi-
ased manner and to corroborate results with quantitative
clinical measures. Limitations of the approach include
use of de-identified genomic and clinical data, precluding
individual contact for more extensive phenotyping, and
lack of specialized clinical data and/or testing to support
particular diagnoses. Nevertheless, the large numbers of in-
dividuals and extensive clinical measures allowed for sta-
tistically significant findings, which can be followed up
with specifically recruited cohorts. Finally, replication of
FHH1/ADH1 prevalence estimates and FHH1 disease asso-
ciations should be possible as independent population
sequencing efforts combining WES and EHR data come
to fruition.
In conclusion, we used a DiscovEHR cohort to develop a
triage method for rapid identification of FHH1 and ADH1
candidate variants, verified by expression and functional
studies. We estimate the prevalence of FHH1 and ADH1
and reveal that FHH1 may be >60-fold more common
than previously reported. As sequencing in clinical prac-
tice becomes more routine, identifying FHH1 and ADH1
individuals in large cohorts may improve clinical care of
these individuals, particularly as we identify comorbidities
Table 4. Sequence Kernel Association Test (SKAT) of Binned Rare CASR Loss-of-Function Variants
Code Code Description # Cases p Value Q-Value
453.9 embolism and thrombosis of unspecified site 705 1.51E14 9.26E12
428.32 diastolic heart failure, chronic 467 4.1E12 1.12E9
788.33 mixed incontinence (male, female) 260 1.03E10 1.59E8
296.2 major depressive disorder, single episode,
unspecified degree
248 3.56E10 4.38E8
790.4 nonspecific elevations of transaminase or
lactic dehydrogenase
277 2.54E9 2.6E7
716.96 arthropathy unspecified, lower leg 306 2.26E7 1.76E5
427.1 paroxysmal ventricular tachycardia 471 8.81E7 4.88E5
820.8 fracture of unspecified part of neck of
femur, closed
205 1.56E6 6.71E5
366.16 senile nuclear sclerosis 4,938 1.59E6 6.76E5
294.2 dementia, without behavioral disturbance 201 1.7E6 6.98E5
274 gouty arthropathy 349 1.71E6 6.99E5
715.15 osteoarthritis, localized, primary, pelvic
region and thigh
293 2.48E6 9.53E5
998.59 other postoperative infection 423 4.42E6 .00016
211.3 benign neoplasm of colon 3,176 8.88E6 .00029
305 alcohol abuse, unspecified drinking behavior 223 9.24E6 .0003
224.6 benign neoplasm of choroid 233 1.67E5 .00051
573.8 other specified disorders of liver 205 2.59E5 .00074
785.6 enlargement of lymph nodes 609 3.01E5 .00083
493.91 asthma, unspecified type, with status
asthmaticus
217 3.69E5 .00097
428.22 systolic heart failure, chronic 472 5.37E5 .0013
521.02 dental caries extending into dentine 248 6.13E5 .0014
794.31 nonspecific abnormal electrocardiogram 339 7.13E5 .0015
715.11 osteoarthrosis, localized, primary, involving
shoulder region
229 7.48E5 .0016
Rare nonsense/frameshift and validated missense loss-of-function variants were combined and association with all clinical phenotypes determined by SKAT. Data-
set for analysis included 25 males (61 5 16.2 years, 96% northern European descent) and 30 females (55.5 5 19 years, 100% northern European descent) with
variants compared against 30,448 individuals without rare CASR variants. Three calls of an ICD9 were required to define a case, and covariates were sex, age, age2,
and first four PCs (see Subjects and Methods). We chose an exploratory cutoff of p < 0.05, significant results were at p < 7.74E5, when corrected for multiple
testing (646 ICD9 codes with R200 cases irrespective of genotype). Variants used for analysis were p.Ala19Pro (c.55G>C), p.Leu37Alafs*11 (c.108dup), p.Ar-
g66His (c.197G>A), p.Met74Leu (c.220A>C), p.Cys101* (c.303C>A), p.Arg227* (c.679C>T), p.Trp293* (c.879G>A), p.Cys395Arg (c.1183T>C), p.Glu399Asp
(c.1197G>C), p.Ser417Cys (c.1250C>G), p.Ala430Thr (c.1288G>A), p.Cys437Arg (c.1309T>C), p.Leu660Pro (c.1979T>C), p.Arg690Cys (c.2068C>T),
p.Phe735Leu (c.2205C>G), p.Asn812Ser (c.2435A>G), p.Lys892* (c.2674A>T), and p.Pro1025Argfs*9 (c.3074delC) (all variants relative to transcript 1, Gen-
Bank: NM_001178065.2).that accompany serum Ca2þ dysregulation and/or altered
CaSR function.Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2020.04.006.Acknowledgments
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